Department of Medicine & Advanced Technology, Monash University, Clayton, Victoria, Australia
Perspective
Rare Cancers and Clinical Trials Progress in the Face of Rarity
Author(s): Senapati Dulal*
Cancer is a formidable adversary, affecting millions of lives worldwide. While common cancers like breast, lung and prostate cancers dominate the
public health landscape, there exists a group of malignancies that are far less prevalent but equally devastating - rare cancers. These rare cancers
pose unique challenges for both patients and healthcare providers. However, there is hope on the horizon, as clinical trials are making significant
progress in the face of rarity, offering new possibilities for those affected by these less common but often aggressive diseases. Rare cancers, also
known as orphan cancers, are those with a lower incidence compared to more prevalent malignancies. Although no universal consensus defines
the threshold for rarity, the American Cancer Society suggests that cancers with an incidence of fewer than six cases per 100,000 people per year .. Read More»
DOI:
10.37421/2577-0535.2023.8.225
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report